Abstract:In recent years, poly(ADP-ribose)polymerase-1 (PARP-1) and histone deacetylase (HDAC) have emerged as significant targets in tumor therapy, garnering widespread attention. In this study, we designed and synthesized two novel phthalazinone PARP-1 inhibitors and dual PARP-1/HDAC-1 inhibitors, named DLC-1-46 containing dithiocarboxylate fragments and DLC-47-63 containing hydroxamic acid fragments, and evaluated their inhibitory activities on enzymes and cells. Among the PARP-1 inhibitors, most compounds exhibited high inhibitory activity against the PARP-1 enzyme, with DLC-1-6 being particularly notable, showing IC50 values <0.2 nM. Notably, DLC-1 demonstrated significant anti-proliferative activity, with IC50 values for inhibiting the proliferation of MDA-MB-436, MDA-MB-231, and MCF-7 cells reaching 0.08, 26.39, and 1.01 μM, respectively. Further investigation revealed that DLC-1 arrested MDA-MB-231 cells in the G1 phase and induced apoptosis in a dose-dependent manner. Among the designed dual PARP-1/HDAC-1 inhibitors, several compounds exhibited potent dual-target inhibitory activity, with DLC-49 displaying IC50 values of 0.53 nM and 17 nM for PARP-1 and HDAC-1, respectively. DLC-50 demonstrated the most potent anti-proliferative activity, with IC50 values for inhibiting the proliferation of MDA-MB-436, MDA-MB-231, and MCF-7 cells at 0.30, 2.70, and 2.41 μM, respectively. Cell cycle arrest and apoptosis assays indicated that DLC-50 arrested the cell cycle in the G2 phase and induced apoptosis in HCT-116 cells. Our findings present a novel avenue for further exploration of PARP-1 inhibitors and dual PARP-1/HDAC-1 inhibitors.

Design, Synthesis and Antitumor Activity Study of PARP-1/HDAC Dual Targeting Inhibitors.

Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis, and Structure-Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition

Olaparib Hydroxamic Acid Derivatives As Dual PARP and HDAC Inhibitors for Cancer Therapy.

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Design, Synthesis and Biological Evaluation of Novel Molecules As Potent PARP-1 Inhibitors.

Design, Synthesis, Biological Evaluation and Molecular Docking Study of Novel Urea-Based Benzamide Derivatives As Potent Poly(adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Discovery of Novel Benzamide Derivatives Bearing Benzamidophenyl and Phenylacetamidophenyl Scaffolds As Potential Antitumor Agents Via Targeting PARP-1.

Design of Selective PARP-1 Inhibitors and Antitumor Studies

Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.

Design and Synthesis of the First PARP-1 and Proteasome Dual Inhibitors to Treat Breast Cancer.

Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (Adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Recent study of dual HDAC/PARP inhibitor for the treatment of tumor.

Design, synthesis, and biological evaluation of a series of benzofuran[3,2-<i>d</i>] pyrimidine-4(3<i>H</i>)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors

Discovery of Novel and Potent PARP/PI3K Dual Inhibitors for the Treatment of Cancer

Design, Synthesis and Biological Evaluation of HDAC and VEGFR Dual Inhibitors as a Multi-targeted Anticancer Agents

Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents